CHC HEALTHCARE GROUP |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48.25 TWD | -2.13% |
|
-8.27% | -21.03% |
| Jun. 12 | CHC Healthcare Group Approves Cash Dividend, Payable on August 1, 2024 | CI |
| May. 03 | CHC Healthcare Group Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 5,944 | 6,128 | 7,035 | 10,146 | 8,046 | - |
| Enterprise Value (EV) 1 | 5,944 | 6,128 | 7,035 | 10,146 | 8,046 | 8,046 |
| P/E ratio | 20.3 x | 17.5 x | 22 x | 24 x | 25.8 x | 12.8 x |
| Yield | - | 5.28% | 4.62% | 3.29% | 4.15% | - |
| Capitalization / Revenue | - | 2.51 x | 2.37 x | 2.62 x | 2.3 x | 1.61 x |
| EV / Revenue | - | 2.51 x | 2.37 x | 2.62 x | 2.3 x | 1.61 x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | - | 34.3 x | -271 x | 24.6 x | 14.3 x | - |
| FCF Yield | - | 2.92% | -0.37% | 4.07% | 6.97% | - |
| Price to Book | - | 1.01 x | 1.15 x | 1.57 x | 1.27 x | - |
| Nbr of stocks (in thousands) | 150,290 | 161,049 | 161,543 | 166,050 | 166,756 | - |
| Reference price 2 | 39.55 | 38.05 | 43.55 | 61.10 | 48.25 | 48.25 |
| Announcement Date | 3/18/21 | 3/23/22 | 3/23/23 | 3/14/24 | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 2,440 | 2,974 | 3,877 | 3,493 | 4,990 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | - | 493.3 | 475.8 | 613.5 | 434.5 | - |
| Operating Margin | - | 20.22% | 16% | 15.82% | 12.44% | - |
| Earnings before Tax (EBT) 1 | - | 491.1 | 483.8 | 559.4 | 406.5 | - |
| Net income 1 | 366.4 | 381.6 | 356.6 | 418.9 | 311.5 | 629 |
| Net margin | - | 15.64% | 11.99% | 10.8% | 8.92% | 12.61% |
| EPS 2 | 1.950 | 2.180 | 1.980 | 2.550 | 1.870 | 3.780 |
| Free Cash Flow 1 | - | 178.7 | -25.97 | 412.9 | 561 | - |
| FCF margin | - | 7.33% | -0.87% | 10.65% | 16.06% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | 46.83% | - | 98.58% | 180.1% | - |
| Dividend per Share 2 | - | 2.010 | 2.010 | 2.010 | 2.000 | - |
| Announcement Date | 3/18/21 | 3/23/22 | 3/23/23 | 3/14/24 | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 876.6 | 606.2 | 692.2 | 817.5 | 858.5 | 800.3 | 886.2 | 737.7 | 1,453 | 657.6 | 865 | 955 | 1,015 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 156.9 | 99.24 | 98.11 | 153.9 | 124.5 | 116.9 | 149.5 | 80.77 | 266.3 | 20.35 | 107.5 | 146 | 161 |
| Operating Margin | 17.9% | 16.37% | 14.17% | 18.82% | 14.51% | 14.6% | 16.87% | 10.95% | 18.33% | 3.09% | 12.43% | 15.29% | 15.86% |
| Earnings before Tax (EBT) 1 | 173.3 | 103 | 130.2 | 137.6 | 113 | 109.2 | 132 | 60.38 | 257.9 | 13.58 | 100.5 | 139 | 154 |
| Net income 1 | 136.1 | 60.2 | 111.3 | 101.4 | 83.68 | 79.25 | 95.56 | 43.27 | 200.8 | 2.263 | 78.5 | 109 | 121.5 |
| Net margin | 15.53% | 9.93% | 16.08% | 12.4% | 9.75% | 9.9% | 10.78% | 5.87% | 13.82% | 0.34% | 9.08% | 11.41% | 11.97% |
| EPS 2 | 0.7500 | 0.3400 | 0.6100 | 0.5600 | 0.4700 | 0.4900 | 0.5800 | 0.2600 | 1.220 | 0.0100 | 0.4700 | 0.6550 | 0.7300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/23/22 | 5/4/22 | 8/3/22 | 11/3/22 | 3/23/23 | 5/4/23 | 8/7/23 | 11/6/23 | 3/14/24 | 5/3/24 | - | - | - |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | 179 | -26 | 413 | 561 | - |
| ROE (net income / shareholders' equity) | - | 6.4% | 5.83% | 6.65% | 4.49% | - |
| ROA (Net income/ Total Assets) | - | 3.17% | 2.81% | 3.17% | 2.22% | - |
| Assets 1 | - | 12,056 | 12,699 | 13,222 | 14,032 | - |
| Book Value Per Share 2 | - | 37.80 | 38.00 | 38.80 | 38.10 | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | 514 | 683 | 550 | 500 | - |
| Capex / Sales | - | 21.07% | 22.95% | 14.18% | 14.31% | - |
| Announcement Date | 3/18/21 | 3/23/22 | 3/23/23 | 3/14/24 | - | - |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
48.25
TWD
Average target price
56.5
TWD
Spread / Average Target
+17.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.03% | 247M | |
| +12.33% | 204M | |
| +26.13% | 77.74M |
- Stock Market
- Equities
- 4164 Stock
- Financials CHC Healthcare Group
